Clinical trials: Severe Pneumonia
Community-acquired Pneumonia
Monotherapy Versus Bitherapy in Non-severe Hospitalized Community-acquired Pneumonia
The purpose of this study is to determine whether a monotherapy with a Beta-Lactam is not inferior to an association of a Beta-Lactam and a macrolide in treating adult patients with community-acquired pneumonia.
- Trial name
- BICAP (NCT00818610)
- Testing
- Beta lactam (amoxicillin / clav. acid OR cefuroxime), Beta-lactam (amoxicillin / clav. acid OR cefuroxime) AND macrolide (clarithromycin)
- Where
- 6 sites in Switzerland
- Volunteers
- 601 people
- Sponsor
- Swiss National Fund for Scientific Research
Coagulopathy, Nosocomial Pneumonia
Effect of Antioxidant Vitamins on Coagulopathy and Nosocomial Pneumonia After Severe Trauma
The purpose of this study is to determine the effect of antioxidant vitamins (vitamins C and E) on the development of coagulation derangements and nosocomial pneumonia after severe trauma in patients.
- Trial name
- NCT01897792
- Testing
- Vitamin C, Vitamin E, Saline (for Vitamin C)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Alabama at Birmingham
COVID-19
Trial of Tocilizumab for Treatment of Severe COVID-19: ARCHITECTS
The overall objective is to evaluate the clinical efficacy and safety of tocilizumab relative to placebo among approximately 300 hospitalized adult patients who have severe COVID-19.
- Trial name
- ARCHITECTS (NCT04412772)
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Queen's Medical Center
Covid19, Viral Pneumonia Human Coronavirus
Methylprednisolone vs. Dexamethasone in COVID-19 Pneumonia (MEDEAS RCT)
Low-dose glucocorticoid treatment is the only intervention shown to significantly reduce mortality in cases of COVID-19 pneumonia requiring oxygen supplementation or ventilatory support.
- Conditions
- Covid19, Viral Pneumonia Human Coronavirus, Severe Acute Respiratory Syndrome
- Trial name
- MEDEAS (NCT04636671)
- Testing
- Methylprednisolone, Dexamethasone
- Where
- Italy
- Volunteers
- 690 people
- Sponsor
- University of Trieste
COVID -19, COVID-19 (Prevention)
A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19.
This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics, anti-drug antibodies, and neutralizing activity of MDX2301 administered by intravenous (IV), intramuscular (IM), or subcutaneous (SC)…
- Trial name
- NCT07445971
- Testing
- MDX2301, Normal Saline
- Where
- 2 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
Covid19
Blood Purification With Seraph 100 Microbind Affinity Blood Filter for Treatment of Severe COVID19 Observational Study
This is a multi-center, observational study that will enroll 1) patients with severe COVID-19 who have agreed to undergo therapy with Seraph® 100 under the existing EUA; 2) patients (medical record data) that have been previously…
- Trial name
- PURIFY-OBS-1 (NCT04606498)
- Testing
- Observational
- Where
- 14 sites in United States
- Volunteers
- 200 people
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
Viral Pneumonia, Serotonin Syndrome
Cyproheptadine in Severe COVID-19 : A Unblinded Randomized Trial
This randomized controled open label clinical trial is to evaluate the effect of Cyproheptadine on the clinical course of patients presenting a severe SARS-COV 2 pneumonia.
- Conditions
- Viral Pneumonia, Serotonin Syndrome, Platelet Dysfunction
- Trial name
- NCT04820751
- Testing
- Cyproheptadine Hydrochloride 4 MG
- Volunteers
- 200 people
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
SARS-CoV Infection
Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection
The purpose of this research is to identify whether or not Angiotensin Receptor Blockers (ARB) can halt the progression to respiratory failure requiring transfer into the intensive care unit (ICU), as well as halt mechanical…
- Trial name
- NCT04340557
- Testing
- Losartan
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Sharp HealthCare
Pneumonia, Viral
Severe Acute Respiratory Infection - Preparedness (COVID-19 and Influenza)
Severe Acute Respiratory Infection (SARI) is defined by the World Health Organization (WHO) as acute respiratory infection with a history of fever ≥38°C and cough for less than 10 days duration that requires hospital admission.
- Trial name
- SARI-PREP (NCT04786301)
- Where
- 2 sites in United States
- Volunteers
- 1,200 people
- Sponsor
- University of Washington
Covid19
The Safety and Efficacy of SCTA01 Against COVID-19 in Patients Admitted to High Dependence or Intensive Care
This is an adaptive, randomized, double-blinded, placebo-controlled, Phase II/III study conducted to evaluate the effect of SCTA01 on participant survival and clinical efficacy in participants with severe COVID-19 admitted to…
- Trial name
- NCT04683328
- Testing
- SCTA01
- Volunteers
- 560 people
- Sponsor
- Sinocelltech Ltd.
COVID-19
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients.
- Trial name
- I-SPY_COVID (NCT04488081)
- Testing
- Remdesivir, Imatinib Mesylate, Dexamethasone
- Where
- 36 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- QuantumLeap Healthcare Collaborative
SARS-CoV Infection, Covid19
Study of SARS-CoV2 Virus (COVID-19) Seroprevalence Among Lyon-Bron Military Health Schools Personnel
Emerging in China in December 2019, Covid-19, whose pathogen is SARS-Cov-2, was declared a global pandemic in March 2020. The clinical presentation is highly variable, ranging from asymptomatic forms to acute respiratory distress…
- Trial name
- SeroCovEms (NCT04516928)
- Testing
- Anti-SARS-CoV2 Serology, Questionnaire
- Where
- France
- Volunteers
- 392 people
- Sponsor
- Direction Centrale du Service de Santé des Armées
COVID-19
Adrecizumab (HAM8101) to Improve Prognosis and Outcomes in COVID-19 Trial
The clinical trial is designed as a prospective, multi-center, double-blind, randomised, placebo-controlled, interventional trial to assess safety, tolerability and efficacy of Adrecizumab (on top of SOC) in patients with…
- Trial name
- AGNES-19 (NCT05156671)
- Testing
- Adrecizumab (HAM 8101)
- Where
- 13 sites in Germany
- Volunteers
- 16 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Pneumonia
Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia
The purpose of this study is to determine whether tifacogin is effective and safe in the treatment of patients with severe community-acquired pneumonia.
- Trial name
- NCT00084071
- Testing
- Tifacogin
- Where
- 150 sites in United States, Argentina and 16 more
- Volunteers
- 2,136 people
- Sponsor
- Novartis Pharmaceuticals
Covid19, Covid-19 ARDS
Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial
This randomized clinical trial was designed and intended to evaluate the efficacy of Remdesivir and Tocilizumab as a treatment for severe Acute Respiratory Distress Syndrome (ARDS) caused by Coronavirus disease 2019 (COVID-19).
- Trial name
- NCT04678739
- Testing
- Remdesivir, Tocilizumab
- Where
- 4 sites in Bangladesh
- Volunteers
- 205 people
- Sponsor
- M Abdur Rahim Medical College and Hospital
SARS-CoV Infection, Covid19
Can the Electronic Nose Smell COVID-19 Antibodies?
Corona Virus Disease (COVID-19), spread worldwide and has become an emergency of major international concern. In March 2020, the WHO declared the COVID-19 outbreak a global pandemic.
- Trial name
- NCT04475575
- Testing
- Aeonose
- Where
- Netherlands
- Volunteers
- 222 people
- Sponsor
- Maastricht University Medical Center
Covid19
Northern Colorado COVID-19 Biobank
The NoCo-CoBio Project is a biobanking effort to store and preserve saliva, nasopharyngeal, stool and blood specimens from SARS-CoV-2 PCR (polymerase chain reaction) positive individuals.
- Trial name
- NoCo-CoBio (NCT04603677)
- Where
- 4 sites in United States
- Volunteers
- 148 people
- Sponsor
- Colorado State University
COVID-19, Thrombosis Pulmonary
Acetylsalicylic Acid in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients With COVID-19
Inflammatory diseases favour the onset of venous thromboembolic events in hospitalized patients. Thromboprophylaxis with a fixed dose of heparin/low molecular weight heparin (LMWH) is recommended if concomitant inflammatory…
- Trial name
- Asperum (NCT04808895)
- Testing
- Acetylsalicylic acid
- Where
- Italy
- Volunteers
- 204 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
COVID-19
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
The purpose of this clinical trial is to learn whether the study medicine prevent symptoms of COVID-19 in adults who have been exposed to household member(s) with a confirmed symptomatic COVID-19 infection.
- Trial name
- NCT05047601
- Testing
- PF-07321332, Ritonavir
- Where
- 170 sites in United States, Argentina and 15 more
- Volunteers
- 2,954 people
- Sponsor
- Pfizer
Psoriasis, Skin Diseases
A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis
This is a dose-ranging study designed to investigate the efficacy and safety of Baricitinib in the treatment of participants with moderate to severe, chronic plaque psoriasis as assessed by the Psoriasis Area and Severity Index…
- Conditions
- Psoriasis, Skin Diseases, Skin Diseases, Papulosquamous
- Trial name
- NCT01490632
- Testing
- Baricitinib
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 271 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.